Authors

• Muneeb Ahmed (ORCID: https://orcid.org/0000-0003-0323-8260)
• William S. Rilling
• Matthew R. Callstrom (ORCID: https://orcid.org/0000-0001-5505-1882)
• Marco Solbiati (ORCID: https://orcid.org/0000-0002-6651-5539)
• Philippe L. Pereira (ORCID: https://orcid.org/0000-0002-9913-2120)
• Damian E. Dupuy (ORCID: https://orcid.org/0000-0003-0524-5982)
• Elena N. Petre
• Mithat Gönen (ORCID: https://orcid.org/0000-0001-8683-8477)
• Alexis Kelekis (ORCID: https://orcid.org/0000-0002-5429-6041)
• Michael C. Soulen (ORCID: https://orcid.org/0000-0001-8136-2123)
• Constantinos T. Sofocleous (ORCID: https://orcid.org/0000-0002-3142-1399)
• Laura Crocetti

Institutions

• University of Pisa (IT)
• Beth Israel Deaconess Medical Center (US)
• Mayo Clinic (US)
• Memorial Sloan Kettering Cancer Center (US)
• Medical College of Wisconsin (US)
• Brown University (US)
• Mayo Clinic in Arizona (US)
• University General Hospital Attikon (GR)
• Mayo Clinic in Florida (US)
• SLK-Kliniken Heilbronn (DE)
• IRCCS Humanitas Research Hospital (IT)
• University of Pennsylvania (US)

Publication Details

Journal

Trials

Published

2025-09-26

DOI

https://doi.org/10.1186/s13063-025-09006-2

Citations

3

Primary Topic

Hepatocellular Carcinoma Treatment and Prognosis

Type

article

Field-Weighted Citation Impact

3.97

Funders

• Boston Scientific Corporation
• Siemens Healthineers
• Ethicon